Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Investigators have discovered why Huntington’s disease is so toxic to cancer cells and are harnessing it as a novel approach to treat cancer.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
Data recently released from Prostate Cancer UK demonstrates that prostate cancer has become the third most common cause of cancer death in the UK, overtaking breast cancer.
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a…
Results of a Phase I study have suggested multisite stereotactic body radiotherapy prior to immunotherapy treatment may improve patient outcomes.
A Phase I trial using a combination of immunotherapy drugs has demonstrated promise for the treatment of advanced solid tumors .
Findings presented at the 2018 ASCO-SITC symposium highlight initial success for a new form of CAR T-cell treatment.